TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04426903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
Study: NCT02314390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Mindfulness-Based Cognitive Therapy
Description: The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual-Mindfulness-Based Cognitive Therapy
Description: The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
Study: NCT02477137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone or tablet
Description: Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
Study: NCT00392821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001
Study: NCT04428281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
Study: NCT02033460

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy, Education and Exercise
Description: Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy, Education and Exercise
Description: Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
Study: NCT03184714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: BiPAP treatment for 3 years
Study: NCT01608854

Intervention type: OTHER
Intervention: Antibiotic Protocol
Description: Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
Study: NCT02306499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI
Description: Intracytoplasmic Sperm Injection
Study: NCT04641624

Intervention type: OTHER
Intervention: ultrasound assessment
Description: soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.

Intervention type: OTHER
Intervention: ultrasound assessment
Description: soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
Study: NCT01984710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC+S System
Study: NCT03013699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cruciferous and Dark Leafy Green Intervention
Description: Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
Study: NCT03962049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linzagolix
Description: A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
Study: NCT04996472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensitivity to phonological rules: Adults
Description: Assess whether adults are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensitivity to semantic category cues: Adults
Description: Assess whether adults show improved learning of OR or family resemblance rules when a semantic category cue is used.
Study: NCT02653404

Intervention type: OTHER
Intervention: IGRA test (QTF-GIT)
Description: blood sample for QFT-GIT will be taken together with other routine blood samples
Study: NCT01042782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 and MitomycinC
Description: RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks
Study: NCT03882931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
Study: NCT04325555

Intervention type: DRUG
Intervention: PrEP
Description: The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
Study: NCT01687374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-84 parathyroid hormone
Description: 100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection daily for 8 weeks.
Study: NCT03990844

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Okra seed
Description: Noodle enriched with 10% and 20% Okra seed flour.
Study: NCT03013699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Dietary Care
Description: Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
Study: NCT03990844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Okra seed
Description: Noodle enriched with 10% and 20% Okra seed flour.
Study: NCT00542815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: 3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Another Phosphate binder (Sevelamer)
Description: Current approved dosing recommendations for 12 weeks
Study: NCT04634669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05 (dextromethorphan-bupropion)
Description: - AXS-05 tablet, taken daily (up to 15 months)
Study: NCT04160221

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12 hours interval
Description: Time interval between treatments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours interval
Description: Time interval between treatments
Study: NCT05402085

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: Subjects will be provided with high protein diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: Subjects will be provided with high fat diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Carbohydrate-Low Glycemic Index Diet
Description: Subjects will be provided with high carbohydrate-low glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Carbohydrate-High Glycemic Index Diet
Description: Subjects will be provided with high carbohydrate-high glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
Study: NCT03697408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: A JAK 1 selective small molecule inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: A mammalian target of rapamycin (mTOR) inhibitor
Study: NCT03128086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Description: A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
Study: NCT01484912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-2
Description: After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
Study: NCT00443560

Intervention type: OTHER
Intervention: Case controlled analysis of epidural labor analgesia patterns
Description: A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses

Intervention type: OTHER
Intervention: Case controlled analysis of epidural labor analgesia patterns
Description: A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
Study: NCT02066090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Description: manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)
Study: NCT04617938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TACUNA plus Wellness Circle
Description: TACUNA provides three virtual workshops (one hour each) that use motivational interviewing and a virtual Wellness Circle (WC). The workshops combine a 30-minute discussion of opioid, alcohol and marijuana use, and social networks with another 30 minutes focused on three different traditional practices (one per workshop). TACUNA was adapted from our three-session workshop, MICUNAY (Motivational Interviewing and Culture for Urban Native American Youth) protocol, which was developed and tested for urban AI/AN adolescents and from focus groups conducted in Year 1. For the Wellness Circle, youth will have members of their social network virtually attend these once-a-month gatherings. The WC will bring people together to celebrate health and wellness and tradition. The WC will focus on the importance of social networks in making healthy choices, and provide discussion on the role that AOD use and engagement in traditional practices among members of their social networks affect their choices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Education Workshop
Description: The virtual opioid education workshop draws from prevention and education materials supplied and recommended by the National AI/AN Technology and Transfer Center, which is funded by SAMHSA. Materials are culturally relevant educational packages addressing opioid use through recorded webinars, toolkits, and other resources.
Study: NCT01832168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Laparoscopic Prostatectomy
Description: Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic Assisted Laparoscopic Prostatectomy
Description: Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
Study: NCT01734928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
Study: NCT04597333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Dinoprostone vaginal insert.
Study: NCT01857947

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: AECOPD Mr proADM
Study: NCT01066858

Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).

Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
Study: NCT03129685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HALED
Description: This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
Study: NCT01016782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0444
Description: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0444
Description: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0444
Description: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Study: NCT03056287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: treadmill aerobic exercise; 3 sessions per week, 40 minutes per session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: treadmill aerobic exercise; 3 sessions per week, 40 minutes per session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
Study: NCT04597333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical ripening balloon.
Description: Double lumen cervical ripening balloon.
Study: NCT02340676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis (ECP)
Description: Participants receive ECP treatment twice a week for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
Study: NCT02129140

Intervention type: DEVICE
Intervention: Hernia graft/mesh
Description: observational group
Study: NCT01832168

Intervention type: OTHER
Group type: OTHER
Intervention: Application of Absorbable Hemostat
Description: Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of dehydrated human amniotic membrane
Description: Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
Study: NCT02209909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin continuation
Description: Patients are randomized to continue aspirin before OPCAB surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin discontinuation
Description: Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
Study: NCT04204642

Intervention type: OTHER
Intervention: CAA patients data collection
Description: Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
Study: NCT02850133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: aerobic exercise training for 36 sessions within 12-16 weeks
Study: NCT01214148

Intervention type: DEVICE
Group type: OTHER
Intervention: ORSIRO - Drug Eluting Coronary Stent
Description: The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
Study: NCT00510952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Protamine Suspension
Description: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
Study: NCT01728038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
Study: NCT03390036

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Hyaluronic Acid with Triamcinolone Hexacetonide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc
Description: Hyaluronic Acid